## INDUSTRY OVERVIEW

The Life Sciences Italian industry is a diversified and strictly interconnected ecosystem of public and private stakeholders that are in deep connection with the digital sector and Artificial Intelligence professionals.

The value of the production of the entire Life Sciences industry is over € 250 billion in 2021, an increase of 6.9% compared to 2020, 10.1% compared to 2019. These figures show that the pandemic and the critical issues emerging in the global supply and production chains did not really affect the growth of the Life Sciences supply chain in Italy.

In Italy, the added value activated by Life Sciences is equal to 10.6% of GDP. The R&D of the pharmaceutical, medical device and biotech industries is equal to approximately 3 billion euros per year (11% of the total in Italy).

Alongside Industry figures, Italy stands out for the high quality of its scientific research: Italian research has been confirmed as the most productive at global level, both in terms of publications and in terms of citations.
The vitality of Italian research also resulted in intense patenting activity; 2,042 Life Sciences patents were filed in 2020 at the Italian patent and trademark office (UIBM), with a consistent growth of +45% compared to 2019.

The competitiveness of Life Sciences and the attractiveness of the ecosystem are confirmed by the number of Venture Capital and Private Equity investments in high-tech companies in Italy: in 2020, the Life Sciences were the main investment target, with 68 deals (37.6% of the total).
These investments also show a consolidated growth trend in recent years: since 2017, Life Sciences have steadily been the leading sector in terms of the number of investments in high-tech companies, with a growth of +143%.

HEALTHCARE

# ITALY ON THE MOVE 2023

ITA ITALIAN TRADE AGENCY


**LOS ANGELES**
1900 Avenue of the Stars
Suite 350
Los Angeles, CA 90067
T. +1 323 879 0950
F. +1 310 203 8335
losangeles@ice.it

**CHICAGO**
401 N. Michigan Avenue
Suite 1720
Chicago, IL 60611
T. +1 312 670 4360
F. +1 312 670 5147
chicago@ice.it

**MIAMI**
1 SE 3rd Avenue
Suite 1000
Miami, FL 33131
T. +1 305 461 3896
F. +1 786 497 8900
miami@ice.it

**HOUSTON**
777 Post Oak Blvd
Suite 320
Houston, TX 77056
T. +1 281 888 4288
F. +1 281 974 3100
houston@ice.it

**NEW YORK**
33 East 67th Street
New York, NY 10065
T. +1 212 980 1500
F. +1 212 758 1050
newyork@ice.it

**ROME**
Via Liszt, 21
00144 Rome, Italy
T. +39 06 59921
F. +39 06 89280353

www.ice.it


INVEST IN ITALY | ITA ITALIAN TRADE AGENCY | Consulate General of Italy San Francisco | INVITALIA | INNOVIT ITALIAN INNOVATION & CULTURE HUB | be


HEALTHCARE

# ITALY ON THE MOVE 2023


**During the 41st annual**
**J.P. Morgan Healthcare Conference**

**Wednesday, January 11, 2023**
**5:00 p.m.**

**INNOVIT - Italian Innovation & Culture Hub**
**710 Sansome St., San Francisco, CA 94111**

In collaboration with: FARMINDUSTRIA | FEDERCHIMICA ASSOBIOTEC Italian Association for the Development of Biotechnology | ALISEI Advanced Life Sciences in Italy

# Panelists

**Brad Loncar - CEO Loncar Investments**

Brad Loncar is a biotechnology industry investor and founder of Loncar Investments. He is the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program.

**Paolo Rizzardi - Co-Founder, Chairman & CEO of Altheia Science**

Paolo Rizzardi, MD combines a strong scientific and clinical background with managerial skills gained over the past 20 years in substantially contributing to successfully developing cell and gene therapy companies in Italy and in the US reaching ATMP market approval. He published over 90 peer-reviewed manuscripts (5800+ citations, h-index 36).

**Pierluigi Petrone - CEO of Euromed Pharma (Petrone Group)**

Pierluigi is a Shareholder and CEO of Petrone Group, holding 30 Companies with branches in Spain, Singapore, USA, Germany and Ireland, operating in the pharmaceutical, parapharmaceutical and health sectors. Chairman of Assoram. Member of the Board of Confindustria Napoli, Member of Gruppo Tecnico Internazionalizzazione of Confindustria – Rome. Italian Chamber of Commerce in Singapore (ICCS) - Chairperson Healthcare Commission. Member of the Board of the Italian Chamber of Cyprus. Chairman of the Executive Committee of SMEs section of Farmindustria. Chairman of the Chemical Industry section of the Industrial Union of Naples.

**Pierluigi Paracchi - CEO and Co-founder Genenta Science**

Pierluigi Paracchi, previously Founder and CEO of Quantica SGR, co-founder Axòn Capital and AurorA Science, Venture Consultant at Sofinnova Partners. Investor in and Board Member of Ethical Oncology Science. Pierluigi is a member of the Assobiotec Executive Committee. He is non-executive Director of Altheia Science, non-executive Chairman at Lipogems International.

**Fabrizio Chines - Chairman & CEO of SIFI S.p.A.**

As a third generation entrepreneur, Fabrizio Chines became CEO of SIFI in 2016 driving the company's growth through M&A, start-up of commercial operations in foreign markets and investments in R&D leading to 9 new product launches. Fabrizio also serves as a member of the Farmindustria's Council and as advisor to Italian VC Panakes Partners.

**Luca Ravagnan - CEO of WISE**

Luca Ravagnan is the CEO of WISE Srl. He holds a PhD in Physics and an Executive MBA at SDA Bocconi. He developed the technology on which WISE is based and co-founded the company in 2011.
He is a Board member of the Lombardy's Life Sciences Cluster and he is an Endeavor Entrepreneur.

**Dawn Bell, PharmD - GlobalDevelopment Head, Strategic Partnerships - Novartis**

Dr. Bell has been starting and scaling life-sciences businesses from academic spinouts to Top 5 Pharma for the past 20 years. Her career spans both buy and sell-side BD&L, portfolio strategy, R&D, and commercialization. She is a start-up thought leader, board director, and advisor for life-science companies, research institutes, CEOs, founders, and innovation accelerators in the US and Europe.

**Patrick Nosker - Partner/Director of Research at Affinity Asset Advisors**

Patrick Nosker is Director of Research and partner at Affinity Asset Advisors, a New York-based healthcare fund. Dr. Nosker holds a PhD in Biochemistry and Quantitative Biomedicine from Rutgers University and holds several patents related to his work in academia.

## Wednesday, January 11, 2023
## 5:00 p.m.

## VENUE

**INNOVIT - Italian Innovation & Culture Hub**

**710 Sansome St., San Francisco, CA 94111**

## AGENDA

**5:00 - 5:10 pm**

**Opening Remarks**

**Sergio Strozzi** - Consul General of Italy in San Francisco

**Antonino Laspina** - Trade Commissioner Italian Trade Agency New York Executive Director for the USA

**5:10 - 5:15 pm**

**"Life Science Ecosystem Presentation"**

**Massimiliano Boggetti** - President - Cluster Alisei

**5:15 - 5:50 pm**

**Panel:**

**"SMEs and start-ups in Italian Life Sciences Industry: growth, innovation, global partnerships"**

**Paolo Rizzardi** - Co-Founder, Chairman & CEO of Altheia Science

**Pierluigi Petrone** - CEO of Euromed Pharma (Petrone Group)

**Pierluigi Paracchi** - Co-founder and CEO of Genenta Science

**Fabrizio Chines** - Chairman & CEO of SIFI S.p.A.

**Luca Ravagnan** - CEO of WISE

**Dawn Bell** - Global Development Head, Strategic Partnerships at Novartis

**Patrick Nosker** - Partner/Director of Research at Affinity Asset Advisors

**Moderator: Brad Loncar** - CEO of Loncar Investments

**5:50 - 6:00 pm**

**Q&A and Close**

**6:00 - 8:00 pm**

**Cocktail & Networking**

# Companies

**Altheia Science**
Thanks to its world-renowned founders Alessandra Biffi and Paolo Fiorina, Altheia develops cutting edge stem cell and CAR-T cell gene therapies for type I diabetes, multiple sclerosis and myeloid disorders, starting clinical development in 2023. Altheia pursues strategic relationships with Milano and Padova Universities and has a strong IP portfolio.

**Euromed Pharma**
Euromed Pharma is an European company authorized to receive, store, and distribute hospital-line pharmaceutical products in Italy, Spain, Ireland and Germany and USA, through our own GDP-compliant warehouses. We act as sole agent and provide order-to-cash and logistic support including 3PL services and tender monitoring and management of the full process of order management and invoicing under our name, bearing all the burden of downstream, reducing the impact on MAH's financials.

**Genenta Science**
Genenta (www.genenta.com) is a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor microenvironment.

**SIFI**
SIFI, founded in 1935 and headquartered in Italy, develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic disorders. SIFI's portfolio includes pharmaceuticals, medical devices and food supplements. SIFI has direct commercial operations in Italy, France, Spain, Romania, Turkey, Mexico and exports to more than 25 countries worldwide.

**WISE**
WISE is an innovative medical device company developing the new generation of implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing using its proprietary Supersonic Technology. The electrodes of WISE are highly ergonomic, conformable, soft and thin, thus allowing a great adhesion, a minimal invasiveness and an excellent adaptability to the nervous tissue.
wiseneuro.com

# Associations

**Farmindustria**
Farmindustria is the Italian Association of Pharmaceutical Industry. It promotes the value of the sector from therapeutic, R&D, economic and social standpoint. It pursues a pharmaceutical policy and regulatory environment to foster the industry's strategic role for the health of the citizens and growth of the country.

**Federchimica - Assobiotec**
Federchimica - Assobiotec is the Italian Association for the Development of Biotechnology whose mission is to encourage and support biotechnology innovation in order to create value, fostering opportunities for economic and employment growth and for cultural and scientific development in Italy.

**Alisei**
ALISEI (Advanced Life Science in Italy) is an Italian Technological Cluster set up to foster interaction between multidisciplinary research, pharmaceutical and biomedical industries, and public and private health bodies to boost research and innovation in Italy. ALISEI is one of the major players at national level in guiding and boosting research and development, innovation, and technology transfer in the life science sector.